DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth

<jats:sec><jats:title>Background and aims</jats:title><jats:p>Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive tumour with a poor prognosis using current treatments. Targeted therapies may offer a new avenue for more effective strategies. Dual-specificity tyrosine regulated kinase 1A (DYRK1A) is a pleiotropic kinase with contradictory roles in different tumours that is uncharacterised in PDAC. Here, we aimed to investigate the role of DYRK1A in pancreatic tumorigenesis.</jats:p></jats:sec><jats:sec><jats:title>Design</jats:title><jats:p>We analysed DYRK1A expression in PDAC genetic mouse models and in patient samples. DYRK1A function was assessed with knockdown experiments in pancreatic tumour cell lines and in PDAC mouse models with genetic reduction of<jats:italic>Dyrk1a</jats:italic>dosage. Furthermore, we explored a mechanistic model for DYRK1A activity.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>We showed that DYRK1A was highly expressed in PDAC, and that its protein level positively correlated with that of c-MET. Inhibition of DYRK1A reduced tumour progression by limiting tumour cell proliferation. DYRK1A stabilised the c-MET receptor through SPRY2, leading to prolonged activation of extracellular signal-regulated kinase signalling.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>These findings reveal that DYRK1A contributes to tumour growth in PDAC, at least through regulation of c-MET accumulation, suggesting that inhibition of DYRK1A could represent a novel therapeutic target for PDAC.</jats:p></jats:sec>